This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF

1 week ago 13

Sara Appino, The Motley Fool

Tue, January 27, 2026 astatine 10:45 AM CST 4 min read

Sold 24,270 shares of IBB; estimated commercialized worth of $3.50 cardinal based connected quarterly mean pricing.
Net presumption worth decreased by $3.50 million.
Represents a 3.27% displacement successful 13F reportable assets nether management.
Rye Brook Capital present holds zero shares, with nary remaining worth successful IBB.
Sale comes amid money downsizing; the presumption was 1.8% of the fund's AUM successful the erstwhile quarter.
These 10 stocks could mint the adjacent question of millionaires ›

Rye Brook Capital LLC sold retired of iShares Biotechnology ETF (NASDAQ:IBB), liquidating 24,270 shares successful an estimated $3.50 cardinal commercialized based connected quarterly mean pricing, according to a caller SEC filing.

According to a SEC filing dated January 26, 2026, Rye Brook Capital LLC sold its full holding of 24,270 shares successful iShares Biotechnology ETF. The estimated transaction worth is $3.50 million, calculated utilizing the mean stock terms during the quarter. The quarter-end presumption worth declined by $3.50 million. The money reported nary remaining shares post-trade.

Rye Brook Capital afloat exited IBB.
Top holdings aft the filing:
- NASDAQ: QQQ: $26.14 cardinal (24% of AUM)
- TSX: U-UN.TO: $15.2 cardinal (14% of AUM)
- NASDAQ: SMH: $12.07 cardinal (11% of AUM)
- NYSEMKT: KWEB: $8.01 cardinal (7.5% of AUM)
- NYSE: NXE: $7.12 cardinal (6.6% of AUM)
As of January 26, 2026, shares were priced astatine $175.85, up 27.4% implicit the past year, with 14.48 percent points of alpha versus the S&P 500
The presumption was 1.8% of the fund's AUM successful the erstwhile quarter

Metric

Value

AUM	$3.34 billion
Price (as of marketplace adjacent January 26, 2026)	$175.85
Dividend yield	0.23%
1-year full return	28.42%

The iShares Biotechnology ETF seeks to way the concern results of an scale composed of U.S.-listed biotechnology stocks, aiming to supply vulnerability to companies engaged successful biotech research, development, and production.
The fund's portfolio consists chiefly of equity securities of biotechnology firms, with astatine slightest 80% of assets invested successful scale components and up to 20% allocated to derivatives and currency equivalents.
Structured arsenic a non-diversified ETF.

The iShares Biotechnology ETF offers targeted entree to the U.S. biotechnology sector, providing investors with a liquid conveyance to enactment successful the industry's maturation and innovation. The fund's strategy emphasizes wide vulnerability to starring biotech companies, balancing established names with emerging innovators. Its standard and index-based attack alteration businesslike assemblage allocation for portfolio managers seeking specialized healthcare exposure.